BMS-986158 (BET bromodomain inhibitor)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-06-05 — The impact of novel bet inhibitors on the treatment armamentarium of Myelofibrosis.: Review (10-year synthesis) catalogs BMS-986158 as an investigational BET bromodomain inhibitor under clinical evaluation in MF alongside pelabresib and INCB057643, sharing the class mechanism of disrupting BRD4-driven inflammatory/fibrotic/proliferative transcription and the class-level hematologic toxicity signal. (novelty: 3)
Open questions
Related
Contributing findings
The impact of novel bet inhibitors on the treatment armamentarium of Myelofibrosis.
05-jun-2026
novelty 3
per-area 3
strengthens